Vomrid Orange Solution 30 ml

Vomrid Orange Solution is an antiemetic medicine. It is used in the treatment of paediatric gastroenteritis in infants and children aged 6 months to 12 years. It is also used in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in children aged six months and above. Nausea is an uneasy feeling in which a person feels an urge to vomit, while vomiting is the natural response to the body to forcefully discharge the stomach contents.

Vomrid Orange Solution contains 'Ondanestron', which belongs to serotonin 5-HT3 receptor antagonists. It works by blocking the action of a chemical called serotonin in the body, which is responsible for causing nausea and vomiting. As a result, Vomrid Orange Solution prevents the sensation of nausea and vomiting caused by cancer chemotherapy.

Vomrid Orange Solution may cause certain side effects in your child, such as feeling of warmth, headache, diarrhoea, and stomach pain. These side effects generally resolve over time. However, if it does not resolve, stop giving this medicine to your child and contact the paediatrician. Do not give more than the prescribed dose of Vomrid Orange Solution to the child. Vomrid Orange Solution can be given with or without food. The dose of the medicine will be decided by your paediatrician.

Vomrid Orange Solution is intended for paediatric use only. Avoid giving Vomrid Orange Solution to your child if he/she is allergic to it. Keep your doctor informed about your child’s health condition, including his current medications and medical history, to rule out any side effects/interactions. Before administration, inform your doctor if your child has liver and kidney disease.

Vomrid Orange Solution contains 'Ondanestron' that belongs to serotonin 5-HT3 receptor antagonists. It works by blocking the action of a chemical called serotonin in the body which is responsible for causing nausea and vomiting. As a result, Vomrid Orange Solution prevents the sensation of nausea and vomiting caused due to cancer chemotherapy.

• Nausea
• Diarrhoea
• Stomach upset
• Indigestion

Avoid giving Vomrid Orange Solution to your child if he/she is allergic to it. Keep your doctor informed about your child’s health condition including his current medications and medical history to rule out any side effects/interactions. Before administration, inform your doctor if your child has liver and kidney disease. This medicine is intended for only paediatric population. Hence not recommended for use in special population (pregnant, breastfeeding mothers) and adults.

Drug-Drug Interactions: Vomrid Orange Solution has interactions with certain medicines. Hence inform your paediatrician about your child’s complete medication history for further prevention of side effects.

Drug-Food Interactions: No interactions found/established. 

Drug-Disease Interactions: Inform your doctor before giving Vomrid Orange Solution if your child has any history of kidney or liver disease.

• Certain food items/medicines are known to cause nausea/vomiting to your child.
• Make your child drink more fluids to avoid dehydration.
• Making your child take a healthy diet that includes lots of fruits and vegetables, nuts, and low-fat dairy products will help to keep your child in good health and avoid chances of nausea and vomiting. 
• Avoid giving greasy or oily foods to your child as this food triggers nausea and vomiting. 

Nausea/Vomiting: Nausea is an uneasy feeling in the stomach that may come and go in waves in which a person feels a strong urge to vomit. It happens before vomiting. Vomiting is the forcible voluntary or involuntary emptying of stomach contents through the mouth. Usually, your child can face nausea and vomiting as the unpleasant effects of cancer therapy after chemotherapy. It is essential to control vomiting and nausea in cancer patients for performing everyday activities of the day. If not controlled, it can lead to mental changes, loss of appetite, malnutrition, and dehydration. Vomrid Orange Solution is used in the treatment of moderately emetogenic cancer chemotherapy in children.